Yuyu Pharmaceutical CEO Robert Yu promoted YP-P10, a dry eye syndrome treatment candidate, during the 2022 American Academy of Ophthalmology (AAO) Conference held in Chicago, U.S., from last Friday to Monday, the company said. 

During the conference, Yu explained YP-P10 to ophthalmologist key opinion leaders, and conducted interviews with several global ophthalmological media outlets such as The Ophthalmologist and Eyes On Eyecare.

“We informed the current status of the YP-P10 research to U.S. ophthalmologists during the AAO conference and received positive feedback, such as expectations for future research results,” Yu said. “The company will participate in various global medical conferences in the future and will continue to promote YP-P10 to global ophthalmologists, including the U.S. and Europe, through the establishment of an English homepage for the introduction of YP-P10 research.”

The company is currently conducting a phase 2 clinical trial for YP-P10 in 240 dry eye syndrome patients at seven U.S. hospitals.

YP-P10 is a biopharmaceutical drug using synthetic peptides. Through preclinical tests, the company has confirmed superior anti-inflammatory effects compared to existing drugs and aims to treat fundamental dry eye syndrome by improving anti-inflammatory and corneal damage.

According to Yuyu, AAO is one of the largest ophthalmology societies worldwide, where more than 32,000 ophthalmologists and faculty gather to share new technologies and information annually.